Emerging research suggest Retatrutide , a dual agonist targeting both GLP-1 and GIP , may represent a promising development for weight treatment. Initial human tests have indicated substantial decreases in body tissue, potentially surpassing other weight-loss treatments. Despite this, additional assessment is required to fully assess its sustained